Diana K. Bowen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Diana K. Bowen has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- David Chu
Division of Urology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
5 shared publications Earl Y. Cheng
Department of Surgery Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA
5 shared publications- Edward M. Gong
Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
5 shared publications - Elizabeth B. Yerkes
Division of Urology, Ann & Robert Lurie Children’s Hospital of Chicago, Chicago, Illinois
5 shared publications - Earl Y. Cheng
Division of Urology, Ann & Robert Lurie Children’s Hospital of Chicago, Chicago, Illinois
4 shared publications Elizabeth B. Yerkes
Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA
4 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (5) , 724-731
Diagnostic Test Characteristics of Renal Ultrasound Findings for High-Risk Bladder in Spina Bifida
Spina bifida (SB) can cause neurogenic bladder dysfunction and renal deterioration. Guidelines recommend renal ultrasound (RUS) for surveillance, but its utility in screening for high-risk bladder is unclear. We evaluated the performance of RUS findings for detecting high-risk bladder in youth with SB. We conducted a retrospective cohort study of patients with myelomeningocele at a pediatric SB clinic who had a RUS within three months of urodynamic studies (UDS). RUS parameters included hydronephrosis, thinned parenchyma, hypoplasia, and scarring. High-risk bladder was defined as end-fill pressures/detrusor leak point pressures of 40 cmH2O or greater. We calculated sensitivity, specificity, and overall diagnostic accuracy (AUC) of RUS parameters for high-risk bladder, adjusting for repeat measurements. Various subgroup and sensitivity analyses were performed. We analyzed 575 UDS-RUS dyads from 244 unique patients. Median age was 7.2 years, 70% had ventricular shunts. 25% of dyads had high-risk bladder. Any hydronephrosis by Society for Fetal Urology (SFU) grading demonstrated an overall sensitivity 50%, specificity 57%, and clustered AUC of 55% for detecting high-risk bladder. RUS had similar performance across additional analyses, including non-ambulatory patients, high-grade hydronephrosis (SFU 3-4), any RUS abnormality, and using Urinary Tract Dilation (UTD) grading instead of SFU grading. Any hydronephrosis had higher test sensitivity for high-risk bladder in fuller bladders on RUS (RUS-bladder volume >75% of UDS-bladder capacity). RUS should not be used alone as a screening tool to identify high-risk bladder in youth with SB given its limited sensitivity and diagnostic utility. UDS remains an essential and necessary tool for surveilling at-risk bladders.
- 1 November 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (5) , 724-731
Diagnostic Test Characteristics of Renal Ultrasound Findings for High-Risk Bladder in Spina Bifida
Spina bifida (SB) can cause neurogenic bladder dysfunction and renal deterioration. Guidelines recommend renal ultrasound (RUS) for surveillance, but its utility in screening for high-risk bladder is unclear. We evaluated the performance of RUS findings for detecting high-risk bladder in youth with SB. We conducted a retrospective cohort study of patients with myelomeningocele at a pediatric SB clinic who had a RUS within three months of urodynamic studies (UDS). RUS parameters included hydronephrosis, thinned parenchyma, hypoplasia, and scarring. High-risk bladder was defined as end-fill pressures/detrusor leak point pressures of 40 cmH2O or greater. We calculated sensitivity, specificity, and overall diagnostic accuracy (AUC) of RUS parameters for high-risk bladder, adjusting for repeat measurements. Various subgroup and sensitivity analyses were performed. We analyzed 575 UDS-RUS dyads from 244 unique patients. Median age was 7.2 years, 70% had ventricular shunts. 25% of dyads had high-risk bladder. Any hydronephrosis by Society for Fetal Urology (SFU) grading demonstrated an overall sensitivity 50%, specificity 57%, and clustered AUC of 55% for detecting high-risk bladder. RUS had similar performance across additional analyses, including non-ambulatory patients, high-grade hydronephrosis (SFU 3-4), any RUS abnormality, and using Urinary Tract Dilation (UTD) grading instead of SFU grading. Any hydronephrosis had higher test sensitivity for high-risk bladder in fuller bladders on RUS (RUS-bladder volume >75% of UDS-bladder capacity). RUS should not be used alone as a screening tool to identify high-risk bladder in youth with SB given its limited sensitivity and diagnostic utility. UDS remains an essential and necessary tool for surveilling at-risk bladders.
- 6 October 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1) , 106315
Constipation status and the enhanced recovery pathway in bladder reconstruction
- 6 October 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1) , 106315
Constipation status and the enhanced recovery pathway in bladder reconstruction
- Open Access
- 17 March 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (3) , 376
Lower Urinary Tract Symptom Scores Among Patients Presenting for Gender Affirming Orchiectomy: An Exploratory Analysis
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.
- 17 March 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (3) , 376
Open AccessLower Urinary Tract Symptom Scores Among Patients Presenting for Gender Affirming Orchiectomy: An Exploratory Analysis
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.
- 6 December 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (2) , 420-425
Continent catheterizable channels: Does “hitching” the bladder reduce complications?
- 6 December 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (2) , 420-425
Continent catheterizable channels: Does “hitching” the bladder reduce complications?
- 23 October 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (1) , 41-46
End-stage and chronic kidney disease in classic bladder exstrophy: A retrospective muti-institutional cohort study
- 23 October 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 21 (1) , 41-46
End-stage and chronic kidney disease in classic bladder exstrophy: A retrospective muti-institutional cohort study
- Open Access
- 12 June 2023
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 16 (s1) , S57-S68
Abstracts of the 2023 World Congress on Spina Bifi da Research & Care – Neurosurgery
- 12 June 2023
- Published by SAGE Publications in Journal of Pediatric Rehabilitation Medicine
- Vol. 16 (s1) , S57-S68
Open AccessAbstracts of the 2023 World Congress on Spina Bifi da Research & Care – Neurosurgery
- 27 June 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 18 (4) , 412.e1-412.e7
Streamlining surgical trays for common pediatric urology Procedures: A quality improvement initiative
- 27 June 2022
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 18 (4) , 412.e1-412.e7
Streamlining surgical trays for common pediatric urology Procedures: A quality improvement initiative
- 7 June 2022
- Published by Wiley in Neurourology and Urodynamics
- Vol. 41 (6) , 1406-1413
Botulinum toxin in patients at‐risk for bladder augmentation: Durable impact or kicking the can?
Purpose: Deferring bladder augmentation (BA) may be desirable in a pediatric neurogenic bladder (NGB) with worsening compliance, but prior studies have questioned whether onabotulinum toxin A (BTX) demonstrates durable improvement in compliance. We present our overall experience with BTX and its role in mitigating the “at‐risk” NGB, as determined by urodynamic characteristics.Methods: A retrospective single‐institution review of all BTX procedures performed during January 2010 to October 2018 was conducted. Patients with 25 cmH2O or detrusor sphincter dyssynergia (DSD); upper tract changes including new hydronephrosis; new or worsening vesicoureteral reflux; or other signs of a hostile urinary tract (i.e., febrile UTIs). UDS risk grades pre and post‐first BTX injection were compared in this “at‐risk” group, when available.Results: Thirty‐nine patients underwent 162 injection procedures over a median follow‐up of 65 months interquartile range (IQR 49–81). Median age at first BTX was 10 years and the median number of BTX injections per patient was 4 (IQR 2–7; range 1–12) with a median time of 6 months between injections (IQR 4–10). Twenty‐six patients were deemed “at‐risk” at the time of first BTX injection, and of those, 16 (61.5%) proceeded to BA at a median of 36 months (IQR 22.5–42). A small number (four) had BA due to upper tract changes or worsening pressures on BTX, while nine patients (five with CKD) proceeded to BA given a lack of sufficient improvement to consider BTX a long‐term viable option. Post‐first BTX UDS demonstrated downgrading of risk group in 38% and 63% using NSBPR and LCH classifications, respectively.Conclusions: Encouraging improvements in the urodynamic risk group were noted in some patients. With careful counseling and follow‐up, BTX may safely extend the time to BA in some “at‐risk” patients.
- 7 June 2022
- Published by Wiley in Neurourology and Urodynamics
- Vol. 41 (6) , 1406-1413
Botulinum toxin in patients at‐risk for bladder augmentation: Durable impact or kicking the can?
Purpose: Deferring bladder augmentation (BA) may be desirable in a pediatric neurogenic bladder (NGB) with worsening compliance, but prior studies have questioned whether onabotulinum toxin A (BTX) demonstrates durable improvement in compliance. We present our overall experience with BTX and its role in mitigating the “at‐risk” NGB, as determined by urodynamic characteristics.Methods: A retrospective single‐institution review of all BTX procedures performed during January 2010 to October 2018 was conducted. Patients with 25 cmH2O or detrusor sphincter dyssynergia (DSD); upper tract changes including new hydronephrosis; new or worsening vesicoureteral reflux; or other signs of a hostile urinary tract (i.e., febrile UTIs). UDS risk grades pre and post‐first BTX injection were compared in this “at‐risk” group, when available.Results: Thirty‐nine patients underwent 162 injection procedures over a median follow‐up of 65 months interquartile range (IQR 49–81). Median age at first BTX was 10 years and the median number of BTX injections per patient was 4 (IQR 2–7; range 1–12) with a median time of 6 months between injections (IQR 4–10). Twenty‐six patients were deemed “at‐risk” at the time of first BTX injection, and of those, 16 (61.5%) proceeded to BA at a median of 36 months (IQR 22.5–42). A small number (four) had BA due to upper tract changes or worsening pressures on BTX, while nine patients (five with CKD) proceeded to BA given a lack of sufficient improvement to consider BTX a long‐term viable option. Post‐first BTX UDS demonstrated downgrading of risk group in 38% and 63% using NSBPR and LCH classifications, respectively.Conclusions: Encouraging improvements in the urodynamic risk group were noted in some patients. With careful counseling and follow‐up, BTX may safely extend the time to BA in some “at‐risk” patients.